Preliminary results of the association of Palbociclib and radiotherapy in metastatic breast cancer patients

There are no published data of the tolerance of combination of Palbociclib and radiotherapy (Palbo-RT). The use of Palbociclib was recently authorized in France for metastatic hormonal receptor (HR) positive HER2 negative breast cancer in association with hormonal therapy in post-menopausal women. A lot of these patients present with symptomatic metastases and they need radiotherapy. The purpose of this paper is to report our very preliminary results of our first patients treated out of research protocols.

http://ift.tt/2xGD4xO